



MEDICAL TIPS

K-VOG TABLETS

Issue III, No. 11, 2022

Prospective Multicenter Observational Study of Voglibose in Type 2 Diabetes – VICTORY

Kalra S et al. US Endocrinology 2020; 16(1): 31.

- Despite the beneficial effect of voglibose on post-prandial hyperglycemia, its usage for management of T2DM remains undetermined.
- In a 12 week, multi-center, prospective, observational study, 1542 adults with uncontrolled T2DM (HbA1c of 7-10%), treated with voglibose as monotherapy or as an add-on therapy were evaluated.
- Primary end-points was HbA1c and secondary end-points evaluated were fasting blood glucose, post prandial blood glucose, body weight and presence of side effects.
- At the end of 12 weeks, a significant reduction in HbA1c, fasting blood glucose and post prandial blood glucose with a low incidence of side effects was observed.

Voglibose, monotherapy or add-on therapy, significantly reduced HbA1c, fasting blood glucose and post prandial blood glucose and was well tolerated in patients with T2DM in a real world setting.

